Organ specific-autoantibodies: Their role as markers and predictors of disease

References

• Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223–243
   PubMedGoogle Scholar
• Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700–706
   PubMed Web of Science ®Google Scholar
• Harel M, Shoenfeld Y. Predicting and preventing autoimmunity, myth or reality?. Ann NY Acad Sci 2006; 1069: 322–345
   PubMed Web of Science ®Google Scholar
• Scofield RH. Autoantibodies as predictors of diseases. Lancet 2004; 363: 1544–1546
   PubMed Web of Science ®Google Scholar
• Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of diseases. J Clin Invest 2001; 108: 1417–1422
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases?. Arthritis Rheum 2007; 56: 1736–1744
   PubMed Web of Science ®Google Scholar
• Larizza D, Calcaterra V, Martinetti M, Negrini R, De Silvestri A, Cisternino M, et al. Helicobacter pylori infection and autoimmune thyroid disease in young patients: The disadvantage of carrying the human leukocyte antigen—DRB1*0301 allele. J Clin Endocrinol Metab 2006; 91: 176–179
   PubMedGoogle Scholar
• Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80: 867–875
   PubMed Web of Science ®Google Scholar
• Anaya JM, Gomez L, Castiblanco J. Is there a common genetic basis for autoimmune diseases?. Clin Dev Immunol 2006; 13: 185–195
   PubMedGoogle Scholar
• Reveille JD. The genetic basis of autoantibody production. Autoimmun Rev 2006; 5: 389–398
   PubMed Web of Science ®Google Scholar
• Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004; 13(350)2068–2079
   Google Scholar
• Alarcon-Segovia D, Alarcon-Riquelme ME, Cardiel MH, Caeiro F, Massardo L, Villa AR, Pons-Estel BA. Grupo latinoamericano de estudio del lupus eritematoso (GLADEL). Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 2005; 52: 1138–1147
   PubMed Web of Science ®Google Scholar
• Fritzler MJ, Fritzler ML. The emergence of multiplexed technologies as diagnostic platforms in systemic autoimmune diseases. Curr Med Chem 2006; 13: 2503–2512
   PubMed Web of Science ®Google Scholar
• Fritzler MJ. Advances and applications of multiplexed diagnostic technologies in autoimmune diseases. Lupus 2006; 15: 422–427
   PubMed Web of Science ®Google Scholar
• Gonzalez-Buitrago JM, Gonzalez C. Present and future of the autoimmunity laboratory. Clin Chim Acta 2006; 365: 50–57
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Glinoer D, Hollowell JG, Brent G. Thyroid function inside and outside of pregnancy: What do we know and what don't we know?. Thyroid 2005; 15: 54–59
   PubMed Web of Science ®Google Scholar
• Hunter I, Greene SA, MacDonald TM, Morris AD. Prevalence and aetiology of hypothyroidism in the young. Arch Dis Child 2000; 83: 207–210
   PubMedGoogle Scholar
• Flynn RW, MacDonald TM, Morris AD, Jung RT, Leese GP. The thyroid epidemiology, audit, and research study: Thyroid dysfunction in the general population. J Clin Endocrinol Metab 2004; 89: 3879–3884
   PubMed Web of Science ®Google Scholar
• Weetman AP. Autoimmune thyroid disease. Autoimmunity 2004; 37: 337–340
   PubMed Web of Science ®Google Scholar
• Caturegli P, Kimura H, Rocchi R, Rose NR. Autoimmune thyroid diseases. Curr Opin Rheumatol 2007; 19: 44–48
   PubMed Web of Science ®Google Scholar
• Sinclair D. Laboratory aspects of thyroid autoantibodies. Autoimmunity 2007; 41: 47–55
   Google Scholar
• Paschke R. Increased levels of auto-antibodies in thyroid diagnostics: Hashimoto thyroidities or Graves disease?. Internist (Berl) 2006; 47: 1193–1194
   PubMedGoogle Scholar
• Kuijpens JL, De Hann-Meulman M, Vader HL, Pop VJ, Wiersinga WM, Drexhage HA. Cell-mediated immunity and postpartum thyroid dysfunction. J Clin Endocrinol Metab 1998; 83: 1959–1966
   PubMed Web of Science ®Google Scholar
• Amino N, Tada H, Hidaka Y. Postpartum autoimmune thyroid syndrome: A model of aggravation of autoimmune disease. Thyroid 1999; 9: 705–713
   PubMed Web of Science ®Google Scholar
• Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Autoimmun Rev 2003; 2: 241–247
   PubMed Web of Science ®Google Scholar
• Jones DE. Primary biliary cirrhosis. Autoimmunity 2004; 37: 325–328
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261–1273
   PubMed Web of Science ®Google Scholar
• Levy C, Lindor KD. Primary sclerosing cholangitis: Epidemiology, natural history, and prognosis. Semin Liver Dis 2006; 26: 22–30
   PubMed Web of Science ®Google Scholar
• Meda F, Zuin M, Invernizzi P, Vergani D, Selmi C. Serum autoantibodies: A road map for the clinical hepatologist. Autoimmunity 2007; 41: 28–35
   Google Scholar
• Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kDa mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525–3531
   PubMed Web of Science ®Google Scholar
• Ishibashi H, Shimoda S, Gershwin ME. The immune response to mitochondrial autoantigens. Semin Liver Dis 2005; 25: 337–346
   PubMed Web of Science ®Google Scholar
• Kisand KE, Metsuka K, Kisand KV, Gershwin ME, Uibo R. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples. J Gastroenterol 2001; 36: 248–254
   PubMed Web of Science ®Google Scholar
• Prince MI, Chetwynd A, Craig WI, Metcalf JV, James OFW. Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53: 865–870
   PubMed Web of Science ®Google Scholar
• Falorni A, Laureti S, Santeusanio F. Autoantibodies in autoimmune polyendocrine syndrome type II. Endocrinol Metab Clin North Am 2002; 31: 369–389, vii
   PubMed Web of Science ®Google Scholar
• Lovas K, Husebye ES. High prevalence and increasing incidence of Addison's disease in western Norway. Clin Endocrinol (Oxf) 2002; 56: 787–791
   PubMed Web of Science ®Google Scholar
• Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison's disease underestimated?. J Clin Endocrinol Metab 1999; 84: 1762
   PubMed Web of Science ®Google Scholar
• Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: Autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev 2002; 23: 327–364
   PubMed Web of Science ®Google Scholar
• Betterle C, Zanette F, Zanchetta R, Pedini B, Trevisan A, Mantero F, Rigon F. Complement-fixing adrenal autoantibodies as a marker for predicting onset of idiopathic Addison's disease. Lancet 1983; 1: 1238–1241
   PubMed Web of Science ®Google Scholar
• Betterle C, Volpato M, Rees Smith B, et al. I: Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ-specific autoimmune diseases. J Clin Endocrinol Metab 1997; 82: 932–938
   PubMedGoogle Scholar
• Betterle C, Volpato M, Rees Smith B, et al. II: Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases. J Clin Endocrinol Metab 1997; 82: 939–942
   PubMed Web of Science ®Google Scholar
• Laureti S, De Bellis A, Muccitelli VI, Calcinaro F, Bizzarro A, Rossi R, et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J Clin Endocrinol Metab 1998; 83: 3507–3511
   PubMedGoogle Scholar
• De Bellis A, Bizzarro A, Rossi R, Paglionico VA, Criscuolo T, Lombardi G, et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab 1993; 76: 1002–1007
   PubMed Web of Science ®Google Scholar
• Miao D, Yu L, Eisenbarth GS. Role of autoantibodies in type 1 diabetes. Front Biosci 2007; 112: 1889–1898
   Google Scholar
• Taplin CE, Barker JM. Autoantibody “subspecificity” in type 1 diabetes. Autoimmunity 2007; 41: 12–19
   Google Scholar
• Skyler JS. Prediction and prevention of type 1 diabetes: Progress, problems, and prospects. Clin Pharmacol Ther 2007; 81: 768–771
   PubMed Web of Science ®Google Scholar
• Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab 2004; 89: 3896–3902
   PubMed Web of Science ®Google Scholar
• Nejentsev S, Sjoroos M, Soukka T, Knip M, Simell O, Lovgren T, et al. Population-based genetic screening for the estimation of type 1 diabetes mellitus risk in Finland: Selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci. Diabet Med 1999; 16: 985–992
   PubMedGoogle Scholar
• Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: The 2-year analysis of the German BABYDIAB study. Diabetes 1999; 48: 460–468
   PubMed Web of Science ®Google Scholar
• Bingley PJ, Williams AJ, Gale EA. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials. Diabetes Care 1999; 22: 1796–1801
   PubMedGoogle Scholar
• LaGasse JM, Brantley MS, Leech NJ, et al. Washington State diabetes prediction study. Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: An 8-year follow-up of the Washington State diabetes prediction study. Diabetes Care 2002; 25: 505–511
   PubMedGoogle Scholar
• Kupila A, Muona P, Simell T, et al. Juvenile diabetes research foundation centre for the prevention of type I diabetes in Finland. Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. Diabetologia 2001; 44: 290–297
   PubMed Web of Science ®Google Scholar
• Hahl J, Simell T, Ilonen J, Knip M, Simell O. Costs of predicting IDDM. Diabetologia 1998; 41: 79–85
   PubMedGoogle Scholar
• Ferber KM, Keller E, Albert ED, Ziegler AG. Predictive value of human leukocyte antigen class II typing for the development of islet autoantibodies and insulin-dependent diabetes postpartum in women with gestational diabetes. J Clin Endocrinol Metab 1999; 84: 2342–2348
   PubMedGoogle Scholar
• Larsson HE, Lynch K, Lernmark B, Nilsson A, Hansson G, Almgren P, et al. Diabetes-associated HLA genotypes affect birthweight in the general population. Diabetologia 2005; 48: 1484–1491
   PubMed Web of Science ®Google Scholar
• Craig D, Robins G, Howdle PD. Advances in celiac disease. Curr Opin Gastroenterol 2007; 23: 142–148
   PubMedGoogle Scholar
• Monsuur AJ, Wijmenga C. Understanding the molecular basis of celiac disease: What genetic studies reveal. Ann Med 2006; 38: 578–591
   PubMed Web of Science ®Google Scholar
• Hoffenberg EJ, Liu E. Celiac disease for the allergist: Who and how to screen. Allergy Asthma Proc 2007; 28: 20–24
   PubMedGoogle Scholar
• Harrison MS, Wehbi M, Obideen K. Celiac disease: More common than you think. Cleve Clin J Med 2007; 74: 209–215
   PubMedGoogle Scholar
• Mearin ML. Celiac disease among children and adolescents. Curr Probl Pediatr Adolesc Health Care 2007; 37: 86–105
   PubMedGoogle Scholar
• Alaedini A, Green PHR. Autoantibodies in celiac disease. Autoimmunity 2007; 41: 20–27
   Google Scholar
• Marmouz F. Adult coeliac disease. Allerg Immunol (Paris) 2007; 39: 23–25
   Google Scholar
• Goddard CJ, Gillett HR. Complications of coeliac disease: Are all patients at risk?. Postgrad Med J 2006; 82: 705–712
   PubMed Web of Science ®Google Scholar
• Holtmeier W. Treatment and management of celiac disease. Z Gastroenterol 2006; 44: 1167–1175
   PubMedGoogle Scholar
• Shoenfeld Y. To smell autoimmunity: Anti-P-ribosomal autoantibodies, depression, and the olfactory system. J Autoimmun 2007; 28: 165–169
   PubMed Web of Science ®Google Scholar
• Irani S, Lang B. New autoantibody mediated disorders of the central nervous system. Autoimmunity 2007; 41: 56–66
   Google Scholar
• Kister I, Herbert J, Swerdlow ML, Bergamaschi R, Piccolo G, Oger J. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 2007; 68: 1326–1327
   PubMedGoogle Scholar
• Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: Past, present, and future. Clin Invest 2006; 116: 2843–2854
   Google Scholar
• Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365–368
   PubMed Web of Science ®Google Scholar
• Gold R, Stangel M, Dalakas MC. Drug insight: The use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3: 36–44
   PubMedGoogle Scholar
• Melms A, Luther C, Stoeckle C, Pöschel S, Schroth P, Varga M, et al. Thymus and myasthenia gravis: Antigen processing in the human thymus and the consequences for the generation of autoreactive T cells. Acta Neurol Scand 2006; 113((suppl. 183))12–13
   Google Scholar
• Rudnicki SA. Lambert–Eaton myasthenic syndrome with pure ocular weakness. Neurology 2007; 68: 1863–1864
   PubMedGoogle Scholar
• Sidnev DV, Karganov MY, Shcherbakova NI, Alchinova IB, Sanadze AG. Antibodies to acetylcholine receptors in patients with different clinical forms of myasthenia and Lambert–Eaton myasthenic syndrome. Neurosci Behav Physiol 2007; 37: 129–131
   PubMedGoogle Scholar
• Caforio AIP, Tona F, Bottaio S, Vinci A, Dequal G, Daliento L, Thiene G, Iliceto S. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 2007; 41: 36–46
   Google Scholar
• Olson TM. Can antiheart autoantibodies predict disease risk in asymptomatic relatives of patients with dilated cardiomyopathy?. Nat Clin Pract Cardiovasc Med 2007; 4: 308–309
   PubMedGoogle Scholar
• Caforio AL, Daliento L, Angelini A, Bottaro S, Vinci A, Dequal G, et al. Autoimmune myocarditis and dilated cardiomyopathy: Focus on cardiac autoantibodies. Lupus 2005; 14: 652–655
   PubMedGoogle Scholar
• Frustaci A, Pieroni M, Chimentic C. Immunosuppressive treatment of chronic non-viral myocarditis. Ernst Schering Res Found Workshop 2006; 55: 343–351
   Google Scholar
• Sitaru C, Mihai S, Zillikens D. The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases. Arch Dermatol Res 2007; 299: 1–8
   PubMed Web of Science ®Google Scholar
• Eming R, Hertl M. Immunoadsorption in pemphigus. Autoimmunity 2006; 39: 609–616
   PubMed Web of Science ®Google Scholar
• Grando SA. Pemphigus in the XXI century: New life to an old story. Autoimmunity 2006; 39: 521–530
   PubMedGoogle Scholar
• Lanza A, Cirillo N, Femiano F, Gombos F. How does acantholysis occur in pemphigus vulgaris: A critical review. J Cutan Pathol 2006; 33: 401–412
   PubMed Web of Science ®Google Scholar
• Balighi K, Taheri A, Mansoori P, Chams C. Value of direct immunofluorescence in predicting remission in pemphigus vulgaris. Int J Dermatol 2006; 45: 1308–1311
   PubMed Web of Science ®Google Scholar
• Huang CH, Chen CC, Wang CJ, Chang YT, Liu HN. Using desmoglein 1 and 3 enzyme-linked immunosorbent assay as an adjunct diagnostic tool for pemphigus. J Chin Med Assoc 2007; 70: 65–70
   PubMedGoogle Scholar
• Taïeb A, Picardo M. VETF members. The definition and assessment of vitiligo: A consensus report of the vitiligo European task force. Pigment Cell Res 2007; 20: 27–35
   PubMedGoogle Scholar
• Kemp EH, Gavalas NG, Gawkrodger DJ, Weetman AP. Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. Autoimmun Rev 2007; 6: 138–142
   PubMed Web of Science ®Google Scholar
• Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 1983; 9: 689–696
   PubMed Web of Science ®Google Scholar
• Lim HW, Hexsel CL. Vitiligo: To treat or not to treat. Arch Dermatol 2007; 143: 643–646
   PubMedGoogle Scholar
• Manga P, Sheyn D, Yang F, Sarangarajan R, Boissy RE. A role for tyrosinase-related protein 1 in 4-tert-butylphenol-induced toxicity in melanocytes: Implications for vitiligo. Am J Pathol 2006; 169: 1652–1662
   PubMedGoogle Scholar
• Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, et al. Unraveling the complex relationship between cancer immunity and autoimmunity: Lessons from melanoma and vitiligo. Adv Immunol 2006; 90: 215–241
   PubMed Web of Science ®Google Scholar
• Garbelli S, Mantovani S, Palermo B, Giachino C. Melanocyte-specific, cytotoxic T cell responses in vitiligo: The effective variant of melanoma immunity?. Pigment Cell Res 2005; 18: 234–242
   PubMedGoogle Scholar
• Hedstrand H, Ekwall O, Olsson MJ, Landgren E, Kemp EH, Weetman AP, et al. The transcription factors SOX9 and SOX10 are vitiligo autoantigens in autoimmune polyendocrine syndrome type I. J Biol Chem 2001; 276: 35390–35395
   PubMedGoogle Scholar
• Yang R, Hellmark T, Zhao J, Cui Z, Segelmark M, Zhao MH, Wang HY. Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with Goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 2007; 18: 1338–1343
   PubMed Web of Science ®Google Scholar
• Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404–418
   PubMed Web of Science ®Google Scholar
• Phelps RG, Rees AJ. The HLA complex in Goodpasture's disease: A model for analyzing susceptibility to autoimmunity. Kidney Int 1999; 56: 1638–1653
   PubMed Web of Science ®Google Scholar
• Borza DB, Hudson BG. Molecular characterization of the target antigens of anti-glomerular basement membrane antibody disease. Springer Semin Immunopathol 2003; 24: 345–361
   PubMed Web of Science ®Google Scholar
• Toh BH, Alderuccio F. Pernicious anaemia. Autoimmunity 2004; 37: 357–361
   PubMed Web of Science ®Google Scholar
• Kumar V. Pernicious anemia. MLO Med Lab Obs 2007; 39(28)30–31
   PubMedGoogle Scholar
• Whittingham S, Mackay IR. Autoimmune gastritis: Historical antecedents, outstanding discoveries, and unresolved problems. Int Rev Immunol 2005; 24: 1–29
   PubMed Web of Science ®Google Scholar
• Levin L, Tomer Y. The etiology of autoimmune diabetes and thyroiditis: Evidence for common genetic susceptibility. Autoimmun Rev 2003; 2: 377–386
   PubMedGoogle Scholar
• Weetman AP, Jenkins RC. Disease associations with autoimmune thyroid disease. Thyroid 2002; 12: 977–988
   PubMedGoogle Scholar
• Golden B, Levin L, Ban Y, Concepcion E, Greenberg DA, Tomer Y. Genetic analysis of families with autoimmune diabetes and thyroiditis: Evidence for common and unique genes. J Clin Endocrinol Metab 2005; 90: 4904–4911
   PubMedGoogle Scholar
• Obermayer-Straub P, Manns MP. Autoimmune polyglandular syndromes. Baillieres Clin Gastroenterol 1998; 12: 293–315
   PubMed Web of Science ®Google Scholar
• Rosatelli MC, Meloni A, Meloni A, Devoto M, Cao A, Scott HS, et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum Genet 1998; 103: 428–434
   PubMed Web of Science ®Google Scholar
• Wolff AS, Erichsen MM, Meager A, Magitta NF, Myhre AG, Bollerslev J, et al. Autoimmune polyendocrine syndrome type 1 in Norway: Phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007; 92: 595–603
   PubMed Web of Science ®Google Scholar
• Goswami R, Gupta N, Ray D, Rani R, Tomar N, Sarin R, Vupputuri MR. Polymorphisms at +49A/G and CT60 sites in the 3′ UTR of the CTLA-4 gene and APECED-related AIRE gene mutations analysis in sporadic idiopathic hypoparathyroidism. Int J Immunogenet 2005; 32: 393–400
   PubMedGoogle Scholar
• Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed 2003; 74: 9–33
   PubMedGoogle Scholar
• Biró E, Szekanecz Z, Czirják L, Dankó K, Kiss E, Szabó NA, et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 2006; 25: 240–245
   PubMed Web of Science ®Google Scholar
• Stagi S, Giani T, Simonini G, Falcini F. Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44: 517–520
   PubMed Web of Science ®Google Scholar
• Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: The PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005; 76: 561–571
   PubMed Web of Science ®Google Scholar
• Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 2004; 18: 677–688
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Atzeni F, Capsoni F, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity 2005; 38: 507–518
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment and systemic lupus erythematosus: An overview. Autoimmunity 2005; 38: 465–472
   PubMed Web of Science ®Google Scholar
• Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs 2006; 7: 451–456
   PubMed Web of Science ®Google Scholar
• Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206–210
   PubMed Web of Science ®Google Scholar
• Mandac JC, Chaudhry S, Sherman KE, Tomer Y. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. Hepatology 2006; 43: 661–672
   PubMed Web of Science ®Google Scholar
• Vallisa D, Cavanna L, Berte R, Merli F, Ghisoni F, Buscarini L. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. Acta Haematol 1995; 93: 31–35
   PubMedGoogle Scholar
• Chatzantoni K, Mouzaki A. Anti-TNF-alpha antibody therapies in autoimmune diseases. Curr Top Med Chem 2006; 6: 1707–1714
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study. Arthritis Res Ther 2006; 8: R3
   PubMed Web of Science ®Google Scholar
• Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, Sarzi-Puttini P. Organ-specific autoantibodies in patients treated with adalimumab: A prospective follow-up study. Autoimmunity 2007; 41: 88–92
   Google Scholar
• Bagnasco M, Grassia L, Pesce G. The management of the patient with unexpected autoantibody positivity. Autoimmun Rev 2007; 6: 347–353
   PubMed Web of Science ®Google Scholar